Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the six-month period from November 1, 2010 to April 30, 2011 (with one scheme extending to May 30, 2011). The report, dated May 11, 2011, details the status of various share option schemes and block listing returns. It does not contain general business operations or financial performance data.
Key Financial Metrics
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly limited to equity compensation scheme statistics.
Material Changes in Share Option Schemes
The filing reports the following changes in unallotted securities across eight distinct schemes during the reporting period:
- GlaxoSmithKline Share Option Plan - Ordinary Shares: Decreased by 832,235 shares (issued/allotted), leaving a balance of 1,260,191.
- GlaxoSmithKline Share Option Plan - ADS: Decreased by 1,555,344 shares (issued/allotted), leaving a balance of 2,452,512.
- GlaxoSmithKline Savings Related Share Option Scheme: Decreased by 1,172,784 shares (issued/allotted), leaving a balance of 3,090,723.
- Other Schemes: No securities were issued or allotted during the period for the Glaxo Wellcome UK, Glaxo Wellcome International, Glaxo Wellcome 1999, and SmithKline Beecham 1989 plans. Their balances remained unchanged from the previous return.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document serves solely as a regulatory update on share scheme inventory.
Investor Verification Checklist
- Verify the total number of shares issued under the GlaxoSmithKline Share Option Plan (Ordinary and ADS) totaling 2,387,579 shares during the period.
- Confirm the remaining unallotted balance for the GlaxoSmithKline Savings Related Share Option Scheme is 3,090,723.
- Note that no new shares were issued under legacy schemes (Glaxo Wellcome and SmithKline Beecham plans) during this six-month window.
- Review the company's annual Form 20-F for comprehensive financial performance data, as this Form 6-K contains no financial metrics.